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Two new triphenylarsonium alkylthiolate precursors, a thiosulfate zwitterion and 
a thioacetate salt, have been structurally characterised and their cytotoxicity 
evaluated against PC3 cells. The arsonium compounds have been used to prepare 
gold nanoparticles decorated with triphenylarsonium groups. 
 
Arsenic has attracted the attention of scientists for centuries and its compounds have a variety 
of applications ranging from electronic and semiconductor materials
1
 to organic reagents, 
arsonium ylides finding utility in the Wittig reaction.
2
 Historically, arsenic compounds have 
been widely investigated for their medicinal properties although interest declined as greater 
understanding of their toxicity became apparent.
3,4
 Generally inorganic As(III) and As(V) 
species are highly toxic, whereas organic arsenic compounds are significantly less toxic.
1,5 
More recently there has been a resurgence of interest in the medicinal properties of arsenic 
compounds, including the use of arsenic trioxide and organic arsenic derivatives as 
treatments for leukaemia and other cancers,
1,3,4
 the characterisation of an arsenic trioxide 
analogue of cisplatin,
6
 and the observation that 
72
As and 
74
As radiopharmaceuticals could be 
useful in positron emission tomography (PET).
1
 
 
 The chemistry of arsenic is broadly similar to that of phosphorus, and organic 
phosphonium salts are known to act as lipophilic cations that are preferentially accumulated 
in the mitochondria of cells.
7
 Similarly, arsonium cations are also lipophilic and 
lipophosphoramidate derivatives containing arsonium head-groups (1)
8
 have been studied as 
 2 
 
gene delivery systems, and 
64
Cu-labelled complexes of 1,4,7,10-tetraazacyclododecane-
4,7,10-triacetic acid-conjugated tri-phenylarsonium cations (2) have been found to act as 
tumour-selective PET imaging agents.
9
 Phosphonium species have been found to be 
extremely valuable for mitochondria-targeted therapeutics and diagnostics. Mitochondrial 
dysfunction is associated with a number of disorders and there is increasing awareness of the 
importance of targeting drugs to this organelle.
7
 Recent work has demonstrated the potential 
of combining phosphonium compounds with nanotechnological approaches to traffic 
pharmaceutical and diagnostic moieties into mitochondria.
10
 For example, incorporation of 
phosphonium groups into the lipid bilayer of liposomes,
11
 or onto the surface of dendrimers
12
 
and polymer nanoparticles,
13
 facilitates their preferential uptake by mitochondria. We have 
prepared phosphonium-functionalised gold nanoparticles
14-16
 which are accumulated by cells 
and localised in the mitochondria.
17
 Inspired by the success of arsonium systems such as 1 
and 2 we decided to broaden the scope of our studies to include triphenylarsonium 
compounds and herein report our preliminary results on the biological properties of 
triphenylarsonium alkylthiosulfate zwitterions (3) and salts (4) and their application in the 
synthesis of triphenylarsonium-functionalised gold nanoparticles (AuNPs). 
 The synthesis of 3, 4 and the triphenylarsoniumalkylthiolate- functionalised AuNPs 
are described in the supplementary information. The structures of 3 and 4 were confirmed by 
x-ray crystallography. Perhaps surprisingly, the structures of few organic thiosulfate 
zwitterions have been reported.
18
 Both compounds display the expected tetrahedral geometry 
around the arsenic atoms with mean C-As-C bond angles of 109.5(2)
o
 in 3 and 109.46(11)
o
 in 
4. In zwitterion 3 (Fig.1), the S-O bonds in the thiosulfate group are similar with a mean 
length of 1.447(4)Å, indicative of multiple bond character, and that the negative charge is 
delocalised over the entire sulfate group. The mean O-S-O angle [113.8(2)
o
] is consistent 
with those in other thiosulfate ions.
18
 The S-S bond length [2.1081(18)Å], is slightly shorter 
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than that of the corresponding phosphonium compound [2.1117(9)Å],
15
 but longer than the S-
S bond in ionic thiosulfate ions such as Me2HN(CH2S2O3)2
-
Na
+
.
18
 Within the crystal lattice 
the zwitterions pack fairly loosely, held together by hydrogen-bonding interactions between 
the sulfate oxygens and the phenyl hydrogens, but there is no close interaction between the 
arsonium and the thiosulfate moieties. The bond lengths and angles of the thioacetate group 
in salt 4 (Fig. 2), are as expected. The molecular packing shows no significant interactions 
between the arsonium centre and the bromide anion or between the bromide and the carbonyl 
group.  
 In order to evaluate the efficacy of the triphenylarsonium-functionalised AuNPs as 
cellular transport systems we first screened the parent arsonium compounds 3 and 4 against 
the PC3 prostate cancer cell line. Cell viability was assessed using MTT and CellTitre-Glo
®
 
assays (Fig. 3.). MTT measures mitochondrial activity to determine the in vitro cytotoxic 
effects of chemical entities. The results showed 3 and 4 to have IC50 values of 75 M and 72 
M, respectively, after 72 hours. These values compare very favourably with those of 
phosphonium compounds, a large number of which have been screened using MTT against 
PC3 cells, and which displayed IC50 values in the range 0.4 - 5 M.
19
 These results are also in 
accordance with cellular toxicity data for lipophosphoramidate derivatives, where 
phosphonium compounds show greater cytotoxicity than the corresponding arsonium 
compounds.
8
 We also used the CellTitre-Glo® assay to confirm the MTT cytotoxicity data. 
This uses luminescence to determine the number of viable cells based on a quantification of 
ATP levels. The data showed a similar trend to that determined using MTT.   
 The cytotoxicity of arsenic compounds is crucially dependent on the nature and 
oxidation state of the species. Inorganic compounds, such as arsenite and arsenate, show 
acute toxicity; for example, the IC50 of sodium arsenate was reported as 6M.
20
 In contrast, 
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the organic derivative arsenobetaine, Me3As
+
CH2CO2
-
, an important metabolite of arsenic 
which is widely distributed in marine ecosystems and found in comparatively high levels in 
seafood, is reported to have no toxic effects and was found to significantly enhance the cell 
viability of bone marrow cells in vitro in a concentration-dependent manner.
20
  
 Phosphonioalkylthiosulfate zwitterions,
15
 and phosphonium alkylthioacetate salts,
16
 
are known to act as ‘masked thiolates’ and under reductive conditions cleavage of the 
thiosulfate S-S or thioacetate S-C bonds, respectively, takes place, generating 
phosphonioalkylthiolate zwitterions that can coordinate to the surface of gold films.  
 We have exploited this chemistry to generate water-soluble cationic gold 
nanoparticles functionalised with alkylthiolate ligands bearing phosphonium head-groups. 
We have now extended this approach to the analogous arsonium compounds. Reduction of 
tetrachloroaurate salts in situ with sodium borohydride in the presence of 3 or 4 in a biphasic 
water/dichloromethane mixture yields the triphenylarsonium-capped AuNPs. Recent work 
has reported rare examples of the coordination chemistry of tertiary arsine ligands bearing 
pendant thiolate groups towards Ni(II), Pt(II) and Pd(II).
21
 However, to the best of our 
knowledge, there are no reports of the coordination chemistry of triorganoarsonium thiolate 
species or of the use of tertiary arsines or arsonium compounds as capping ligands in the 
formation of functionalised nanoparticles, although nanoscale liposomes or nanobins, 
composed of lipids and metal salts, have been used to encapsulate and stabilise arsenic 
trioxide in order to extend the clinical utility of this compound.
22
 The triphenylarsonium-
AuNPs can be purified by extraction with dichloromethane followed by freeze drying. The 
UV-Vis spectrum of a typical sample of arsonium-capped nanoparticles shows an absorption 
band with max of 520 nm. High resolution TEM analysis of the AuNPs derived from the 
thiosulfate zwitterions is shown in Fig.4, and revealed the AuNPs to have spherical shapes. 
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Size distribution analysis of 1000 particles using Abel imaging software revealed a mean 
diameter of 2.7 ± 0.9nm. This compares favourably with the corresponding phosphonium-
capped AuNPs which have an average particle size of 3.0 ±1.2 nm. Wide scan XPS spectra of 
the arsonium-AuNPs contained signals due to Au, S, As and C, with the gold displaying the 
characteristic doublet for Au (4f7/2) and Au (4f5/2) with binding energies of ca 83.9 and 87.5 
eV respectively, indicative of the presence of Au(0).
14
 Research is now ongoing to   
understand the cellular uptake of the triphenylarsonium-AuNPs and confirm their presence 
inside the cells using TEM to realise their potential intracellular transport properties.  
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Fig. 1. Molecular structure of zwitterion 3. 
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Fig. 2. Molecular structure of thioacetate salt 4. 
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Fig. 3. Cell viability studies of triphenylarsonium derivatives 3 and 4: (a), Cell Titre Glo 
assay of zwitterion 3; (b) Cell Titre Glo assay of thioacetate salt 4; (c), MTT assay of 3; (d) 
MTT assay of 4. 
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Fig. 4. TEM image of arsonium-AuNP derived from zwitterion 3 and associated particle size 
histogram. 
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